Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
When sourcing reference material for receptor pharmacology or analytical verification workflows, confirm CAS 2381089-83-2, lot identifiers, and COA-backed purity data rather than informal naming alone
the study's lead author and a professor of radiology in the University of Pennsylvania Perelman School of Medicine, said in a statement that the findings were "observational" and do not "definitively confirm an association between GLP-1 medications and reduced breast cancer incidence," however the study "does add to the growing body of evidence suggesting that it's worth investigating these weight-loss drugs as potential cancer prevention tools." Narula reiterated that the new study is "hypothesis-generating" not "practice-changing," though the study does add to a growing body of similar research
In clinical weight loss trials, patients on Semaglutide lost an average of 14.9% of their body weight within 68 weeks
10.7554/eLife.00772 eLife 34 KarchJ.MolkentinJ
44 (2.7%) of patients on semaglutide died due to causes related to cardiovascular disease, compared to 46 (2.8%) in the placebo group
